Imprimis Pharmaceuticals has filed for registration of its recently constructed New Jersey facility with the U.S. Food and Drug Administration (FDA) as a 503B outsourcing facility. The state-of-the-art facility is expected to begin manufacturing as an outsourcing facility in December 2016 and dispensing medications in early first quarter 2017. The NJ-based outsourcing facility will initially make and distribute Imprimis’ proprietary sterile Dropless Therapy injectable and LessDrops topi...